Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Receivables: 2013-2024

Historic Change in Receivables for ImmunityBio (IBRX) over the last 4 years, with Dec 2024 value amounting to $2.4 million.

  • ImmunityBio's Change in Receivables rose 214.77% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 562.09%. This contributed to the annual value of $2.4 million for FY2024, which is N/A change from last year.
  • Latest data reveals that ImmunityBio reported Change in Receivables of $2.4 million as of FY2024, which was up 3,246.67% from -$75,000 recorded in FY2015.
  • In the past 5 years, ImmunityBio's Change in Receivables registered a high of $2.4 million during FY2024, and its lowest value of $2.4 million during FY2024.
  • Moreover, its 1-year median value for Change in Receivables was $2.4 million (2024), whereas its average is $2.4 million.